An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis.

Trial Profile

An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Adenovirus infections; Infectious conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 04 Jul 2014 Last checked against ClinicalTrials.gov record.
    • 25 Aug 2011 Results published in Cataract & Refractive Surgery Today
    • 18 May 2011 Primary endpoint 'Sustained-microbiological-response 20% greater than placebo' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top